Ian Blance is joining OTC Valuations as vice president of strategic sales, responsible for driving business development for OTC Val globally.
Blance, 44, recently left Interactive Data after 12 years in a variety of senior positions in their market leading Fixed Income Evaluations business in London and New York and has over 20 years experience in the financial markets.
“We are very pleased that Ian Blance has decided to join OTC Val and are looking forward to him leading the development of this growing business in Europe, North America, and abroad. We believe that Ian’s track record and experience in the valuations industry will be an excellent asset to our business as it develops over the coming few years,” says Bob Sangha, managing director, OTC Val.
“I am very excited about working with such an innovative and dynamic company as OTC Val. OTC derivative activity has exploded in recent years. The Bank for International Settlements recently reported that notional amounts outstanding of OTC derivatives stood at $516 trillion at the end of June 2007, an annualized compound increase of 33% over the previous three years. The development of independent valuations of derivatives has struggled to keep up with this growth and the recent market turmoil only highlights the need for a robust and objective source. Having spent some time assessing the evolving derivative valuations market, I believe that OTC Val has a compelling service offering to meet the challenges that the industry now faces,” adds Blance.